Current Challenges and Obstacles to Drug Development for Chagas Disease
Journal Title: Drug Designing & Intellectual Properties International Journal - Year 2018, Vol 2, Issue 2
Abstract
Chagas disease is a protozoan infection which was first identified more than one hundred years ago. But even now, drugs to treat the latent and chronic phases of the disease are not available. The success of a drug design is highly dependent on activity and toxicity. In the case of Chagas disease, questions remain as to identifying the best treatment (mainly for the chronic phase), and how new drugs and drug combinations compare to current therapy. The principal priority of this mini-review is to report the enormous difficulty that pharmaceutical chemists encounter in the development of new drugs for neglected tropical infectious diseases, in this case Chagas disease. Chagas disease is one of the 17 neglected diseases and was identified 109 years ago by the Brazilian physician and researcher Carlos Justiniano Ribeiro Chagas. Also known as American trypanosomiasis, Chagas disease is endemic in 21 Latin American countries [1-5]. Due to an increasingly globalized world, this parasite has spread to the United States, Japan, Australia, Canada, and even across the European continent [6,7]. It is caused by the hemoflagellate protozoan from the Kinetoplastida order of the Trypanosamatidae family, called Trypanosoma cruzi [2,8,9]. Treatment is restricted to two nitroheterocyclic drugs: nifurtimox (1) and benznidazole (2) (Figure 1). These were discovered during the 1960s and 1970s, respectively [10,11]. Both drugs are more effective in the acute phase of the disease than in the indeterminate and chronic phases [12-21]. Furthermore, there are differences in the efficacies of these drugs in relation to the several strains of T. cruzi [22] (Figure 1).
Authors and Affiliations
Cauê Benito Scarim, Chung Man Chin
Keywords
Related Articles
- EP ID EP587739
- DOI 10.32474/DDIPIJ.2018.02.000134
- Views 156
- Downloads 0
The Frey Effect of Microwave Sonic Weapons
State Department evacuates a number of Americans from the U.S. consulate in Guangzhou, China after they experienced unexplained health issues. A group of U.S. diplomats stationed in China have been brought back to the st...
Regulatory Inflation in Pharmaceutical Drug Development?
During the last decade, and exponentially over the last three years, numerous pharmaceutical manufacturing plants have closed their doors following current Good Manufacturing Practices (cGMP) audits from various agencies...
Nutrigenomics: Opportunities and Challenges in Bangladesh
The Authors of this article has been working on ethnopharmacology and natural product science for the last one decade. They have been involved with several ethnic and traditional medication system development projects an...
Body on Chip-A Distant Dream or an Emerging Reality?
We are currently facing a global health challenge regarding the way we discover and develop new drugs. Small biotech companies, as well as large pharmaceutical corporations, spend increasingly more money on the c...
Extra-Marital Affair Can Lead Trauma and Connections in Higher Risk for Heart Disease in Indian Women
An Extra-marital affair relationship can break heart. Extramarital affair women, according to a study, have a higher risk for heart disease. Turns out, for women, being extra-marital affair can be injurious to health. Ac...